Next Article in Journal
Transpulmonary Plasma Endothelin-1 Arterial:Venous Ratio Differentiates Survivors from Non-Survivors in Critically Ill Patients with COVID-19-Induced Acute Respiratory Distress Syndrome
Previous Article in Journal
Comparison of Mitochondrial Genome Expression Differences among Four Skink Species Distributed at Different Latitudes under Low-Temperature Stress
Previous Article in Special Issue
Phage Display Revealed the Complex Structure of the Epitope of the Monoclonal Antibody 10H10
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 19
10.3390/ijms251910638
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice

by
Thomas Fischer
1,
Christopher Dietrich
2,
Felix Dietlein
3,
Sergio Muñoz Vázquez
1,
Beate Zimmermanns
1,
Philipp Krapf
1,4,
Ferdinand Sudbrock
1,
Alexander Drzezga
1,4,5,
Markus Dietlein
1 and
Klaus Schomäcker
1,*
1
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany
2
Institute and Polyclinic for Occupational Medicine, Environmental Medicine, and Preventive Research Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany
3
Computational Health Informatics Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
4
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine (INM-5), Wilhelm-Johnen-Straße, 52428 Jülich, Germany
5
German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Venusberg-Campus 1/99, 53127 Bonn, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(19), 10638; https://doi.org/10.3390/ijms251910638
Submission received: 20 August 2024 / Revised: 26 September 2024 / Accepted: 29 September 2024 / Published: 2 October 2024
(This article belongs to the Special Issue Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy 3.0)
Versions Notes

Abstract

This study evaluates the efficacy of [131I]I-ERIC1 in targeting and inhibiting the growth of SCLC tumors in mice, focusing on tumor accumulation and regression and potential side effects. NCAM-positive NCI-H69 SCLC cells were implanted in CB 17 SCID mice, and [131I]I-ERIC1 biokinetics were measured in organs and tissues at four post-injection time points (24, 72, 96, and 120 h). The experimental series compared tumor growth, survival, and changes in blood counts among three treatment groups (1, 2, or 3 MBq) and a control group, with treatments initiated either two or five days post implantation. [131I]I-ERIC1 was synthesized with >95% radiochemical purity and a specific activity of 15 TBq/mmol. Tumor activity peaked at 31.5 ± 6.6% ID/g after four days, demonstrating significant antitumor efficacy, which resulted in sustained remission and extended survival. Hematological toxicity was observed, with the optimal dose identified as 2 MBq per animal administered two days post implantation. [131I]I-ERIC1 shows promise as a theranostic agent for personalized cancer treatment by effectively targeting SCLC tumors with manageable side effects. However, further studies are required to optimize dosing strategies and minimize toxicity.
Keywords: nuclear medicine; theranostics; SCLC; biokinetics; anti-NCAM antibody; ERIC1; I-131; mice; tumor growth inhibition nuclear medicine; theranostics; SCLC; biokinetics; anti-NCAM antibody; ERIC1; I-131; mice; tumor growth inhibition

Share and Cite

MDPI and ACS Style

Fischer, T.; Dietrich, C.; Dietlein, F.; Vázquez, S.M.; Zimmermanns, B.; Krapf, P.; Sudbrock, F.; Drzezga, A.; Dietlein, M.; Schomäcker, K. Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice. Int. J. Mol. Sci. 2024, 25, 10638. https://doi.org/10.3390/ijms251910638

AMA Style

Fischer T, Dietrich C, Dietlein F, Vázquez SM, Zimmermanns B, Krapf P, Sudbrock F, Drzezga A, Dietlein M, Schomäcker K. Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice. International Journal of Molecular Sciences. 2024; 25(19):10638. https://doi.org/10.3390/ijms251910638

Chicago/Turabian Style

Fischer, Thomas, Christopher Dietrich, Felix Dietlein, Sergio Muñoz Vázquez, Beate Zimmermanns, Philipp Krapf, Ferdinand Sudbrock, Alexander Drzezga, Markus Dietlein, and Klaus Schomäcker. 2024. "Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice" International Journal of Molecular Sciences 25, no. 19: 10638. https://doi.org/10.3390/ijms251910638

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop